文献速递胸部肿瘤

简报:IMscin001 第2部分(皮下 vs 静脉阿替利珠单抗治疗局部晚期或转移性NSCLC的随机III期研究)更新数据

Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC.
PubMed 文献 · J Thorac Oncol · 2024-05-09

IMscin001研究更新分析显示,局部晚期或转移性NSCLC患者接受皮下阿替利珠单抗1875 mg(n=247)或静脉1200 mg(n=124)每3周一次,中位随访9.5个月时两组中位OS相似(10.7 vs 10.1个月,HR 0.88,95%CI 0.67-1.16),其他疗效、免疫原性、患者报告结局及安全性均相似。

要点

  • 皮下阿替利珠单抗1875 mg与静脉1200 mg每3周一次的中位OS相似(10.7 vs 10.1个月,HR 0.88,95%CI 0.67-1.16)。
  • 中位皮下注射时间为7.1分钟,75.7%的患者平均注射时间在4至8分钟之间。
  • 大多数医疗保健从业者认为皮下给药方便(79.5%)、易于操作(89.7%)且对治疗满意(84.6%)。

核心结论

  • 成熟OS数据在皮下与静脉阿替利珠单抗两组间相似,更新后的疗效与安全性特征与既往结果一致且等同于静脉阿替利珠单抗。

研究设计与样本

  • IMscin001(NCT03735121)随机III期研究,纳入年龄大于或等于18岁的局部晚期或转移性NSCLC患者,按2:1随机接受皮下阿替利珠单抗1875 mg(n=247)或静脉阿替利珠单抗1200 mg(n=124),每3周一次。

主要发现

  • 更新分析中位生存随访为9.5个月,皮下组与静脉组中位OS分别为10.7个月与10.1个月(HR 0.88,95%CI 0.67-1.16)。
  • 其他疗效终点、免疫原性、患者报告结局及安全性在两组间相似。
  • 中位皮下注射时间为7.1分钟,大多数患者(75.7%)的平均皮下注射时间为4至8分钟。
  • 79.5%的医疗保健从业者认为皮下给药方便,89.7%认为易于操作,84.6%对治疗满意,75.0%同意皮下给药相比静脉给药可节省时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Subcutaneous atezolizumab is approved for the treatment of various solid tumors. Previous results from the IMscin001 study (NCT03735121) revealed that the pharmacokinetics, efficacy, immunogenicity, and safety of subcutaneous and intravenous atezolizumab were consistent (data cutoff: April 26, 2022). We present updated data from this trial (data cutoff: January 16, 2023). METHODS: Eligible patients aged above or equal to 18 years with locally advanced or metastatic NSCLC were randomized (2:1) to receive atezolizumab subcutaneously (1875 mg, n = 247) or intravenously (1200 mg, n = 124) every 3 weeks. Here, we present updated efficacy (overall survival [OS]; progression-free survival; objective response rate; duration of response), safety, and immunogenicity end points, alongside patient-reported outcomes and health care practitioner (HCP) perspectives. RESULTS: In this updated analysis, the median survival follow-up was 9.5 months. Median subcutaneous injection time was 7.1 minutes, with an average subcutaneous injection time of 4 to 8 minutes in most patients (75.7%). OS data were mature: median OS was similar between treatment arms, at 10.7 and 10.1 months in the subcutaneous and intravenous arms, respectively (hazard ratio: 0.88; 95% confidence interval: 0.67-1.16). Other efficacy end points, as well as immunogenicity, patient-reported outcomes, and safety, were similar between arms. Most HCPs found subcutaneous administration convenient (79.5%), easy to administer (89.7%), and were satisfied with the treatment (84.6%); 75.0% of HCPs agreed that administering atezolizumab subcutaneously compared with intravenously could save time. CONCLUSIONS: In this analysis, mature OS data were similar between treatments. The updated efficacy and safety profile of subcutaneous atezolizumab is consistent with previous findings and equivalent to intravenous atezolizumab.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Burotto M, Zvirbule Z, Alvarez R, et al. Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC. J Thorac Oncol. 2024. PMID: 38729426. doi:10.1016/j.jtho.2024.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。